AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports - Reuters

Core Impact Points

• AstraZeneca and Bristol Myers Squibb are reportedly in talks to merge in a $400 billion deal.
• The potential tie-up could create one of the largest pharmaceutical companies in the world.
• The deal could have significant implications for the US pharmaceutical market and consumers.
• AstraZeneca and Bristol Myers Squibb have a combined market value of over $400 billion.
• The merger could lead to significant cost savings and increased research and development capabilities.
• The deal could also lead to job losses and changes in the US pharmaceutical landscape.